Fujian Cosunter Pharmaceutical 广生堂
25 significant filings since 29 May 2026: 2 on share pledge, 16 on share issue and 2 on change of interest, and 3 other kinds. The latest, on 2 Sep 2026: 关于持股5%以上股东因公司向特定对象发行股票导致持股比例被动稀释至5%以下的权益变动提示性公告.
自 29 May 2026 起有 25 份重大公告：share pledge 2 份、share issue 16 份、change of interest 2 份，另有 3 类。最新一份（2 Sep 2026）：关于持股5%以上股东因公司向特定对象发行股票导致持股比例被动稀释至5%以下的权益变动提示性公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 15 Aug 2017 | 西南证券 | 朱国广,何治力 | Buy 买入 | ▼ | Outperform 增持 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 中邮证券 | 盛丽华,辛家齐 | Buy 买入 | 20 May 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 1 report. 每行为该券商近十二个月的最新研报；1 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。